Finasteride NDC 17856-0090

NDC codes

FDA NDC Directory

Product NDC (as listed)17856-0090Labeler and product segments. Claims need a package NDC.

Product NDC at billing width17856-0090Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
17856-0090-1	17856009001	1 TABLET, FILM COATED in 1 POUCH (17856-0090-1)Marketed from Jan 11, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Finasteride
Generic name (nonproprietary): finasteride
Active ingredients: Finasteride — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Atlantic Biologicals Corps
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 090121
Marketing start: May 28, 2010
Listing expires: Dec 31, 2026
Other FDA classes: 5-alpha Reductase Inhibitors (Mechanism)
Identifiers: Product ID 17856-0090_385463d5-f3d9-96c0-e063-6294a90ac25eSPL ID 385463d5-f3d9-96c0-e063-6294a90ac25eSPL set ID 29e59387-120c-4367-9f87-75cb53b6460dRxCUI 310346UNII 57GNO57U7G
Pharmacologic class: 5-alpha Reductase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N417856009001 followed by a unit qualifier and the quantity

Package 17856-0090-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 24, 2025.

Indications (excerpt from the label)

Finasteride, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( ): 1.1 Improve symptoms Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) ( ). 1.2 : Finasteride is not approved for the prevention of prostate cancer ( ). Limitations of Use 1.3 1.2 Combination with Alpha-Blocker Finasteride tablets USP, 5 mg admini…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 090121

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 090121
Product	Strength	Form · route	Labeler	Product NDC
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	Proficient Rx LP	63187-265
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	Bryant Ranch Prepack	71335-0433
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	NuCare Pharmaceuticals,Inc.	68071-3354
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	NuCare Pharmaceuticals,Inc.	68071-3380
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	Bryant Ranch Prepack	71335-1634
Finasteride	Finasteride 5 mg/1	Tablet, Film coatedOral	Accord Healthcare, Inc.	16729-090